Nuvalent, Inc. recently reported new clinical and preclinical data for its investigational ROS1-selective inhibitor zidesamtinib at the AACR 2026 meeting, alongside confirmation that the FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results